PMID- 28096656
OWN - NLM
STAT- MEDLINE
DCOM- 20170515
LR  - 20181202
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 11
DP  - 2017
TI  - Analysis of pramipexole dose-response relationships in Parkinson's disease.
PG  - 83-89
LID - 10.2147/DDDT.S112723 [doi]
AB  - BACKGROUND: Pramipexole (PPX), a non-ergot dopamine receptor agonist, is a 
      first-line treatment for Parkinson's disease (PD). A critical dose level above 
      which a better benefit-to-harm ratio exists has not been examined. METHODS: 
      Chinese PD patients (n=464) were retrospectively analyzed by PPX maintenance 
      dose, PD stage, combined levodopa dose, and baseline tremor contribution. The sum 
      score of Baseline Activities of Daily Living (part II) and Motor Examination 
      (III) of the Unified Parkinson's Disease Rating Scale (UPDRS II+III) was used as 
      a covariate for final score adjustment. RESULTS: Sustained-release (SR) and 
      immediate-release (IR) PPX showed similar efficacy based on score changes at 18 
      weeks, with comparable tolerability. Approximately two-third of patients received 
      PPX at >/=1.5 mg/d, and one fourth of patients had >/=20% tremor contribution to 
      UPDRS II+III. After treatment, patients receiving PPX >/=1.5 mg/d showed better 
      improvement in UPDRS II+III scores (P=0.0025), with similar trends with the IR 
      and SR formulations. Patients with >/=20% tremor contribution showed better 
      improvement in UPDRS II+III scores (P=0.0017). No differences were seen based on 
      PD stage or combined levodopa dose. The overall proportions of adverse events 
      (AEs) were similar. More patients discontinued because of intolerable side 
      effects, and more investigator-defined drug-related AEs were recorded in the <1.5 
      mg/d subgroup. CONCLUSION: UPDRS II+III improvement was better with PPX >/=1.5 than 
      with <1.5 mg/d in Chinese PD patients after 18 weeks of treatment, with similar 
      trends seen with IR and SR formulations. The frequency of AEs in PPX >/=1.5 and 
      <1.5 mg/d subgroups was similar.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong 
      University School of Medicine, Shanghai.
FAU - Sun, Sheng-Gang
AU  - Sun SG
AD  - Department of Neurology, Union Hospital Affiliated to Tongji Medical College of 
      Huazhong University of Science and Technology, Wuhan.
FAU - Zhu, Sui-Qiang
AU  - Zhu SQ
AD  - Department of Neurology, Tongji Hospital Affiliated to Tongji Medical College of 
      Huazhong University of Science and Technology, Wuhan.
FAU - Liu, Chun-Feng
AU  - Liu CF
AD  - Department of Neurology, The Second Affiliated Hospital of Soochow University, 
      Suzhou.
FAU - Liu, Yi-Ming
AU  - Liu YM
AD  - Department of Neurology, Qilu Hospital Affiliated to Shandong University, Jinan.
FAU - Di, Qing
AU  - Di Q
AD  - Department of Neurology, Nanjing Brain Hospital, Nanjing.
FAU - Shang, Hui-Fang
AU  - Shang HF
AD  - Department of Neurology, West China Hospital Affiliated to Sichuan University, 
      Chengdu.
FAU - Ren, Yan
AU  - Ren Y
AD  - Department of Neurology, First Affiliated Hospital of China Medical University, 
      Shenyang.
FAU - Xiang, Wei
AU  - Xiang W
AD  - Medical Department, Boehringer Ingelheim (China) Investment Co., Ltd., Shanghai, 
      People's Republic of China.
FAU - Chen, Sheng-Di
AU  - Chen SD
AD  - Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong 
      University School of Medicine, Shanghai.
LA  - eng
PT  - Journal Article
DEP - 20161223
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Antiparkinson Agents)
RN  - 0 (Benzothiazoles)
RN  - 83619PEU5T (Pramipexole)
SB  - IM
MH  - Antiparkinson Agents/*administration & dosage/adverse effects/*therapeutic use
MH  - Benzothiazoles/*administration & dosage/adverse effects/*therapeutic use
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Parkinson Disease/diagnosis/*drug therapy
MH  - Pramipexole
MH  - Retrospective Studies
PMC - PMC5207331
OTO - NOTNLM
OT  - Parkinson's disease
OT  - dose dependent
OT  - pramipexole
OT  - retrospective
COIS- Ying Wang has participated in clinical trials sponsored by GSK, Eisai, Lundbeck, 
      and Novartis. Sheng-Gang Sun has participated in clinical trials sponsored by 
      Novartis, Servier, Eisai, GSK, and Lundbeck. Sui-Qiang Zhu has participated in a 
      clinical trial sponsored by UCB. Chun-Feng Liu has participated in clinical 
      trials sponsored by Pfizer, UCB, and GSK. Yi-Ming Liu has participated in a 
      clinical trial sponsored by UCB. Qing Di has participated in a clinical trial 
      sponsored by Pfizer. Hui-Fang Shang has participated in clinical trials sponsored 
      by GSK and UCB. Yan Ren reports no conflicts of interest in this work. Sheng-Di 
      Chen has participated in clinical trials sponsored by Novartis, Lundbeck, Eisai, 
      and Xian Janssen. All aforementioned authors served as investigators in this 
      retrospective analysis sponsored by Boehringer Ingelheim (China) Investment Co., 
      Ltd. Wei Xiang is employee of Boehringer Ingelheim (China) Investment Co., Ltd. 
      The authors report no other conflicts of interest in this work.
EDAT- 2017/01/18 06:00
MHDA- 2017/05/16 06:00
PMCR- 2016/12/23
CRDT- 2017/01/19 06:00
PHST- 2017/01/19 06:00 [entrez]
PHST- 2017/01/18 06:00 [pubmed]
PHST- 2017/05/16 06:00 [medline]
PHST- 2016/12/23 00:00 [pmc-release]
AID - dddt-11-083 [pii]
AID - 10.2147/DDDT.S112723 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2016 Dec 23;11:83-89. doi: 10.2147/DDDT.S112723. eCollection 
      2017.